18 September 2024
18 September 2024 MJ Gleeson plc (GLE.L) (“Gleeson” or “the Group” or “the Company”) Audited results for the year ended 30 June 2024 (“FY2024”)…
18 September 2024 Advanced Medical Solutions Group plc (“AMS” or the “Group”) Interim results for the six months ended 30 June 2024 ~…
18 September 2024 RESULTS FOR THE YEAR ENDED 31 MAY 2024 Progress on strategic priorities and portfolio transformation Continued business momentum despite macro-economic challenges…
18 September 2024 Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis New indication supported by the MANDARA trial which showed nearly 60% of…
17 September 2024
Euronext acquires leading research and market data benchmarking provider Substantive Research Amsterdam, Brussels, Dublin, Lisbon, London, Milan, Oslo and Paris – 17 September 2024…
B.P. Marsh & Partners Plc (AIM: BPM), the specialist venture capital investor in early stage financial services businesses, is pleased to provide the market…
Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma accepted for regulatory review in Japan · Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials…
Strong sales, a prime portfolio and an improving outlook underpin increased dividend Henry Boot PLC, a Company engaged in land promotion, property investment and…